文献速递中医内科中药与中成药合理使用

橘红痰咳口服液缓解社区获得性肺炎症状的多中心随机对照试验

Effects of Juhongtanke oral solution on alleviating the symptoms of community-acquired pneumonia: A multicenter, prospective, randomized controlled trial.
PubMed 文献 · Front Pharmacol · 2022-10-20

该多中心前瞻性随机对照试验纳入240例社区获得性肺炎患者,比较常规治疗联合橘红痰咳口服液(20 mL q8h,5天)与单纯常规治疗的疗效。结果显示联合治疗组第5天BCSS评分及VAS咳嗽、呼吸困难评分均显著低于对照组,症状缓解率更高,未见明显不良反应,住院时长无差异。

要点

  • 橘红痰咳口服液联合常规治疗可显著降低CAP患者第5天BCSS评分。
  • 联合治疗组VAS咳嗽和呼吸困难评分及缓解率均优于对照组。
  • 两组住院时长无差异,研究中未见明显不良反应。

核心结论

  • 橘红痰咳口服液可考虑用于缓解社区获得性肺炎的临床症状。

研究设计与样本

  • 多中心、前瞻性、随机对照试验,共纳入240例社区获得性肺炎患者,每组120例。
  • 治疗组给予橘红痰咳口服液20 mL q8h联合常规治疗5天,并继续3天安全性观察。

主要发现

  • 第5天BCSS评分中位差值为1分[95%CI (1.00, 2.00)],治疗组显著低于对照组(p < 0.001)。
  • 第5天VAS咳嗽项中位差值为2分[95%CI (1.40, 2.50)],呼吸困难项中位差值为1分[95%CI (0.50, 2.00)],治疗组均显著低于对照组(均p < 0.001)。
  • BCSS缓解率治疗组99.50% vs 对照组89.17%(p = 0.01)。
  • VAS咳嗽项缓解率治疗组98.33% vs 对照组75%(p < 0.001),呼吸困难项缓解率治疗组88.33% vs 对照组62.50%(p < 0.001)。
  • 两组住院时长中位数均为7天,无差异(p = 0.871),研究中未见明显不良反应。

关键数值与推荐

  • 橘红痰咳口服液用法为20 mL q8h,疗程5天。
  • 主要结局为第5天BCSS评分。

临床怎么用

  • 对社区获得性肺炎患者,可在常规治疗基础上联合橘红痰咳口服液以缓解咳嗽、咳痰和呼吸困难症状。
  • 联合用药期间可关注症状缓解情况,本研究未观察到明显不良反应。

局限性

  • 原文摘要未报告盲法、分配隐藏及具体不良反应数据等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: The timely alleviation of symptoms is essential for managing community-acquired pneumonia (CAP). Juhongtanke oral solution is a traditional marketed Chinese patent medicine believed to ease CAP symptoms. The currently available evidence is based on a few retrospective studies of patients with various types of pneumonia, whereas robust randomized controlled trials (RCTs) that support this notion are lacking. Material and methods: In this multi-center, prospective RCT, patients were randomly allocated to receive routine treatment alone or a combination of Juhongtanke oral solution (20 mL q8h) for 5 days and maintained for an additional 3-day safety observation period. The primary outcome was Breathlessness, Cough, and Sputum Scale (BCSS) score evaluated on day 5. Secondary outcomes included the evaluation of cough and dyspnea items in the Visual Analogue Scale (VAS) from days 1-5, remission rate in BCSS and VAS during the treatment course, and the length of hospitalization and in-hospital mortality. Results: Of 272 patients assessed for eligibility, 240 were enrolled in the study (n =120 per group). The mean difference in BCSS evaluated on day 5 was a median 1 point [95%CI (1.00, 2.00)], significantly lower in the treatment group compared with the control group (p < 0.001). Similar results were observed in VAS on day 5, with statistics of a median 2 points [95%CI (1.40, 2.50)] in the cough item and a median 1 point [95%CI (0.50, 2.00)] in the dyspnea item, significantly lower in the treatment group compared with the control group (both p < 0.001). The treatment group had a favorable outcome in BCSS and VAS remission rate assessments compared with the control group, with 99.50% vs. 89.17% in BCSS (p = 0.01), 98.33% vs. 75% in the cough item of VAS (p < 0.001), and 88.33% vs. 62.50% in the dyspnea item of VAS (p < 0.001), respectively. No notable adverse effects were observed during the study. No differences were observed in the length of hospitalization between groups (with a median of 7 days for both groups, p = 0.871). Conclusion: Juhongtanke oral solution may be considered to alleviate the clinical symptoms of CAP.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liang M, Hu L, Luo N, et al. Effects of Juhongtanke oral solution on alleviating the symptoms of community-acquired pneumonia: A multicenter, prospective, randomized controlled trial. Front Pharmacol. 2022. PMID: 36339599. doi:10.3389/fphar.2022.1027901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。